NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗癲癇藥的全球市場 (2020-2027年)

Global Antiepileptic Drugs Market - 2021-2028

出版商 DataM Intelligence 商品編碼 972288
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
抗癲癇藥的全球市場 (2020-2027年) Global Antiepileptic Drugs Market - 2021-2028
出版日期: 2021年07月07日內容資訊: 英文 180 Pages
簡介

老年人口的增加推動了全球抗癲癇藥市場的增長,飲食是全球抗癲癇藥市場增長的主要驅動力之一。此外,大量的管道藥物正在推動市場增長。

本報告提供全球抗癲癇藥市場相關調查,提供市場概要,各市場區隔及地區別的市場分析與預測,競爭情形分析,並提供主要企業簡介等資訊。

目錄

第1章 全球抗癲癇藥市場:調查範圍·手法

  • 調查手法
  • 調查目的·調查範圍

第2章 全球抗癲癇藥市場:市場定義·概要

第3章 全球抗癲癇藥市場:摘要整理

  • 市場明細:各類醫藥品
  • 市場明細:各給藥途徑
  • 市場明細:各流通管道
  • 市場明細:各地區

第4章 全球抗癲癇藥市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球抗癲癇藥市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 醫療費償付分析
  • 未滿足需求

第6章 全球抗癲癇藥市場:COVID-19分析

  • 市場上Covid-19分析
    • COVID-19:以前的市場方案前
    • COVID-19:目前市場方案
    • COVID-19:以後或未來方案
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 疫情期間與市場有關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球抗癲癇藥市場:各類醫藥品

  • 簡介
    • 市場規模分析·與前一年同期比較成長分析(%):各類醫藥品
    • 市場魅力指數:各類醫藥品
  • 第一世代抗癲癇藥
  • 第二世代抗癲癇藥
  • 第三代抗癲癇藥

第8章 全球抗癲癇藥市場:各給藥途徑

  • 簡介
    • 市場規模分析·與前一年同期比較成長分析(%):各給藥途徑
    • 市場魅力指數:各給藥途徑
  • 口服
  • 靜脈內

第9章 全球抗癲癇藥市場:各流通管道

  • 簡介
    • 市場規模分析·與前一年同期比較成長分析(%):各流通管道
    • 市場魅力指數:各流通管道
  • 醫院藥局
  • 藥局
  • 其他

第10章 全球抗癲癇藥:各地區

  • 簡介
    • 市場規模分析·與前一年同期比較成長分析(%):各地區
    • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析·與前一年同期比較成長分析(%):各類醫藥品
    • 市場規模分析·與前一年同期比較成長分析(%):各給藥途徑
    • 市場規模分析·與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析·與前一年同期比較成長分析(%):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球抗癲癇藥:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第12章 全球抗癲癇藥:企業簡介

  • GW Pharmaceuticals, plc
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.

第13章 重要考察

第14章 DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMPH2827

Market Overview

The global antiepileptic drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

The antiepileptic drugs are medications that are developed for the purpose of idiopathic and asymptomatic treatment of seizures and epilepsy. In addition to epilepsy and seizures, antiepileptic drugs can also be taken for the purpose of treatment of neuropathic pain.

Market Dynamics

The global antiepileptic drugs market growth is driven by the expanding base of geriatric population, dietary habits are some of the significant factors that are triggering growth of the global antiepileptic drugs market.

Large number of pipeline drugs is driving the growth of the market

The market is driven by advancement in drugs modification. Over the past several periods, the number of available antiepileptic drugs has more than doubled, many of the presently available antiepileptic drugs have basics pharmacokinetics and more small effects on liver metabolism that converts into a lower rate of side effects.

The large number of pipeline drugs is driving the growth of the market. The expected launch of drugs currently in the pipeline, such as Ganaxolone by Marinus Pharmaceuticals, Inc., Perampanel by Eisai Co., Ltd., USL261 by Upsher Smith Laboratories, Inc., and YKP3089 by SK Life Sciences, Inc. is a high impact rendering driver of the epilepsy drugs market.

VX765 by Vertex Pharmaceuticals, Inc. and YKP3089 by SK Life Sciences, Inc. are some of the Phase IIb drugs. Phase III clinical trials include NRL-1 intranasal Diazepam, Carbamazepine IV, Diazepam Auto-injector (Vanquix), and Topiramate Extended-Release (USL-255).

Rising awareness levels about epilepsy coupled with strategic alliances are anticipated to stimulate the market growth.

Increasing number of people being affected with different types of cancer is another factor driving the growth of the antiepileptic drug market. Chemotherapy is one of the standard treatments used to deal with cancer and is also accompanied by side effects of nausea and vomitting. In fact, chemotherapy actually accounts for the largest share of all the applications of the global antiepileptic drugs market. This factors are driving the growth of the market in the forecast period.

Rising generic competition is likely to hinder the market growth

However, the market is threatened by generic competition, which has risen dramatically in the face of patent expirations among various major branded antiepileptic drugs. This factor will hamper the market growth in the forecast period.

COVID-19 Impact Analysis

There is no evidence that people with epilepsy alone have a weakened immune system. They should not be considered "immunocompromised" and would not have an "immune deficiency" from having seizures. People with different types of epilepsy, certain causes of epilepsy or other health conditions may have factors affecting their immune system. However, patients with tumor-related, drug-resistant epilepsy, insomnia, and economic difficulties are at a higher risk of increased seizure frequency. Some people with epilepsy regardless of seizure control have other health conditions that put them at higher risk from COVID-19.

Segment Analysis

Second generation anti-epileptics segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The second-generation anti-epileptics drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.

Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018, one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

In September 2019, GW Pharmaceuticals, plc, a biopharmaceutical company headquartered in the U.K., unveiled that it received approval from the European Commission (EC) for EPIDYOLEX, an innovative drug that will be used for Dravet syndrome or Lennox-Gastaut syndrome (LGS), as an adjunctive therapy of seizures. It is meant for patients who are 2 years of age and older. It will be launched across Europe. These factors are driving the growth of the market in the forecast period.

The hospital pharmacy are expected to dominate the antiepileptic drugs market during the forecast period

The hospital pharmacies held the largest share in the antiepileptic drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global antiepileptic drugs market

North America region is dominating the global antiepileptic drugs market accounted for the largest market share, owing to well-established health care infrastructure, technological advancements, and favorable government support in the region. The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer's disease. About one percent of Americans have some form of epilepsy, and nearly four percent (1 in 26) will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson's disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the antiepileptic drugs market.

Competitive Landscape

The antiepileptic drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GW Pharmaceuticals, plc, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiepileptic drugs market globally.

Sanofi S.A

Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.

Product Portfolio: The Company's portfolio comprised of drugs, generic medicines, food supplement, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.

Why Purchase the Report?

  • Visualize the composition of the antiepileptic drugs market segmentation by drugs, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in antiepileptic drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Antiepileptic Drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antiepileptic drugs market report would provide an access to an approx. 61 market data table, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Antiviral Drugs Market - By Drugs

  • First Generation Anti-epileptics
  • Second Generation Anti-epileptics
  • Third Generation Anti-epileptics

Global Antiviral Drugs Market -By Route of Administration

  • Oral
  • Intravenous

Global Antiviral Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Antiviral Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Antiepileptic Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antiepileptic Drugs Market - Market Definition and Overview

3. Global Antiepileptic Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drugs
  • 3.2. Market snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Antiepileptic Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the new drug approvals over the past few years
      • 4.1.1.2. Increase in the Cases of Epilepsy
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antiepileptic Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Antiepileptic Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antiepileptic Drugs Market - By Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Segment
    • 7.1.2. Market Attractiveness Index, By Drugs Segment
  • 7.2. First Generation Anti-epileptics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Second Generation Anti-epileptics
  • 7.4. Third Generation Anti-epileptics

8. Global Antiepileptic Drugs Market - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Intravenous

9. Global Antiepileptic Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Antiepileptic Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Antiepileptic Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Antiepileptic Drugs Market- Company Profiles

  • 12.1. GW Pharmaceuticals, plc, *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. GlaxoSmithKline PLC
  • 12.4. Johnson & Johnson
  • 12.5. Novartis AG
  • 12.6. Pfizer, Inc.
  • 12.7. Sanofi SA
  • 12.8. Sunovion Pharmaceuticals Inc.
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. UCB S.A.

LIST NOT EXHAUSTIVE

13. Global Antiepileptic Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us